Tag Archives: Huntington’s disease

April, 2018

August, 2017

  • 31 August

    FDA Approves Teva’s Austedo for Treatment of Tardive Dyskinesia in Adults

    JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved AUSTEDO® (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults. AUSTEDO® was previously approved for the treatment of chorea associated with Huntington’s disease in April 2017. Tardive dyskinesia is a …

July, 2017

  • 14 July

    New Data Network for Huntington’s Disease Research

    Huntington’s disease is an hereditary disorder of the nervous system caused by a faulty gene on chromosome four. The faulty gene leads to cell death in neurons in the brain resulting in gradual physical, mental and emotional changes, and ultimately death. Those born to a parent with Huntington’s disease have …

April, 2017

October, 2016

  • 21 October

    FDA Accepts Resubmission of Teva’s Huntington Disease Drug

    JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the New Drug Application (NDA) for SD-809 (deutetrabenazine) for the treatment of chorea associated with Huntington disease (HD). The FDA has assigned a Prescription Drug User Fee …

December, 2015

October, 2015

March, 2015